Dermatitis

Disease1 paper

Trial sponsors

Azidus Brasil
Company1 trialPhase 396 people
Mayo Clinic
1 trialEarly phase 13 people

Latest

6

EBioMedicineHumans22 Sep

Age-related changes of FCGR3A⁺ natural killer cells and their association with elderly atopic dermatitis

MedicineHumans15 Sep

Association between health-related quality of life and noncommunicable diseases in South Korea: A nationwide representative study

Clinics in DermatologyReview11 Sep

Where the Future Lies: GLP-1 Receptor Agonists as Therapeutics for Dermatologic Comorbidities

GLP-1 receptor agonists

BiochimieReview8 Sep

Selenium in aging and longevity

Preprints.orgReviewPreprint4 Sep

Atopic Dermatitis and Bone Fragility: Osteoimmunological Pathways, Therapeutic Paradoxes, and Risk-Adapted Screening Across the Lifespan

Frontiers in MicrobiologyReview4 Sep

Skin microbiome and cutaneous aging mechanisms and clinical implications

Microbiome composition

ADA Scientific Sessions 2025 AbstractHuman trial13 Jun

Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist—Preliminary Results from a Phase 1 Study